The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Long-term survival of patients with CLL treated with ibrutinib compared to age-matched controls
Jan Burger, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the long-term survival of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. The study compared the survival rates of these patients to an age-matched US population, revealing that long-term survival rates are now similar, suggesting that with new targeted therapies, many patients with CLL can expect a life expectancy comparable to their healthy peers. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: AstraZeneca, BeiGene, Abbvie; Speaker Fees: Janssen.
